These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 5134859)

  • 21. [Vaccination against influenza in the elderly. Experience with adjuvant vaccines].
    Baldo V; Menegon T; Buoro S; Scalici C; Vesco A; Perale S; Boato W; Carletti M; Bonello C; Dalla Costa D; Trivello R
    Ann Ig; 1999; 11(5):369-74. PubMed ID: 10596424
    [No Abstract]   [Full Text] [Related]  

  • 22. NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 2. SHORT-TERM ANIMAL TOXICITY TESTS.
    PECK HM; WOODHOUR AF; METZGAR DP; MCKINNEY SE; HILLEMAN MR
    Proc Soc Exp Biol Med; 1964 Jun; 116():523-30. PubMed ID: 14193391
    [No Abstract]   [Full Text] [Related]  

  • 23. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water in-oil emulsion.
    SALK JE; BAILEY ML; LAURENT AM
    Am J Hyg; 1952 May; 55(3):439-56. PubMed ID: 14933383
    [No Abstract]   [Full Text] [Related]  

  • 25. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
    de Jong JC; Osterhaus AD
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the current status of oil adjuvants in foot--and--mouth disease vaccines.
    McKercher PD; Graves JH
    Dev Biol Stand; 1976; 35():107-12. PubMed ID: 198275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin E as an adjuvant in an Escherichia coli J5 vaccine.
    Hogan JS; Weiss WP; Smith KL; Todhunter DA; Schoenberger PS; Williams SN
    J Dairy Sci; 1993 Feb; 76(2):401-7. PubMed ID: 8445093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Making better influenza virus vaccines?
    Palese P
    Emerg Infect Dis; 2006 Jan; 12(1):61-5. PubMed ID: 16494719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
    N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vaccination against influenza by adjuvant vaccine in Japan].
    Noriki H; Tate H
    Nihon Eiseigaku Zasshi; 1966 Apr; 21(1):1-10. PubMed ID: 6008110
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.
    McElhaney JE; Coler RN; Baldwin SL
    Expert Rev Vaccines; 2013 Jul; 12(7):759-66. PubMed ID: 23885821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of immune and adverse effects induced by AdjuVac and Freund's complete adjuvant in New Zealand white rabbits (Oryctolagus cuniculus).
    Powers JG; Nash PB; Rhyan JC; Yoder CA; Miller LA
    Lab Anim (NY); 2007 Oct; 36(9):51-8. PubMed ID: 17885664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Influenza vaccination. The importance of antigen amount and adjuvant with reference to the humoral antibody formation after influenza vaccination. A comparative double-blind study with various vaccines].
    Sarateanu DE; Ehrengut W
    Fortschr Med; 1981 Sep; 99(34):1348-52. PubMed ID: 7026399
    [No Abstract]   [Full Text] [Related]  

  • 34. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvanted influenza vaccines.
    Even-Or O; Samira S; Ellis R; Kedar E; Barenholz Y
    Expert Rev Vaccines; 2013 Sep; 12(9):1095-108. PubMed ID: 24053401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influenza vaccination, development and testing of an influenza vaccine].
    Belian W; Henne K; Hölzer E; Wachtel S; Neubert G; Hantsch H; Rux C
    Dtsch Gesundheitsw; 1972 Nov; 27(48):2286-8. PubMed ID: 4656835
    [No Abstract]   [Full Text] [Related]  

  • 37. Seasonal influenza vaccine provides priming for A/H1N1 immunization.
    Del Giudice G; Stittelaar KJ; van Amerongen G; Simon J; Osterhaus AD; Stöhr K; Rappuoli R
    Sci Transl Med; 2009 Dec; 1(12):12re1. PubMed ID: 20371459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of oil-adjuvant influenza vaccine in an industrial population.
    Howell RW
    Br J Ind Med; 1967 Jan; 24(1):66-70. PubMed ID: 6017141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The case for an adjuvanted equine influenza vaccine.
    Kucera CJ
    J Am Vet Med Assoc; 1969 Jul; 155(2):281-4. PubMed ID: 5797155
    [No Abstract]   [Full Text] [Related]  

  • 40. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.